Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics

Acta Oto-Laryngologica

Volumn 119, Issue 2, 1999, Pages 277-280

  Schmid, M ^a,b   Gode U ^a   Schafer D ^a   Wigand, M E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Fuerth Hospital   (Germany)

Author keywords

Aspirin intolerance; Asthma; Nasal polyps

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; MALE; MEDIATOR RELEASE; NOSE MUCOSA; NOSE POLYP; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; SYMPTOMATOLOGY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; ASPIRIN; ASTHMA; BRONCHIAL PROVOCATION TESTS; CASE-CONTROL STUDIES; DINOPROSTONE; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; LEUKOTRIENES; MALE; NASAL MUCOSA; NASAL POLYPS; NEOPLASM RECURRENCE, LOCAL;

EID: 2442757233     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016489950181819     Document Type: Article

References (25)

1. Widal F, Abrami P, Lermoyez J. First complete description of the aspirin idiosyncrasy-Aspirine asthmanasal polyposis syndrome (plus urticaria) 1922. J Asthma 1987; 24: 297-300.
2. Samter M, Beers RF. Concerning the nature of intolerance to aspirin. J Allergy 1967; 40: 281-93.
3. Settipane GA. Aspirin and allergic disease: a review Am J Med 1983; 74: 102-9.
4. Dahlén B, Dahlén SE. Intolerance reactions to NSAIDs. In: Basomba A, Sastre J: ECACI '95 Proceedings I; Bologna 1995: 821-8.
5. Szczeklik A. Aspirin-induced asthma: an update and novel findings. Adv Prostaglandin Thromboxane Leukot Res 1994; 22: 185-98.
6. Knapp HR, Sladek K, Fitzgerald GA. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med 1992; 119: 48-51.
7. Wigand ME, Hosemann W. Microsurgical treatment of recurrent nasal polyps. Rhinol 1989; 8: 25-30.
8. Schmitz-Schumann M, Juhl E, Costabel U, et al. Analgetikaprovokationsproben bei Analgetika-Asthma-Syndrom. Atemwegs-und Lungenkrankheiten 1985; 11: 479-86.
9. Reinke M, Hoppe U, Röder T, Bestmann HJ, Mollenhauer J, Brune K. A monoclonal antibody against the sulfidopeptide leukotrienes LTC4, LTD4 and LTE4. Biochem Biophys Acta 1991; 1081: 274-8.
10. Brune K, Reinke M, Lenz R, Peskar BA. Monoclonal antibodies against E- and F-type prostaglandins. FEBS 1985; 2644 (189): 46-50.
11. Ogino S, Irifune M, Harada T, Kikumori H, Matsunaga T. Arachidonic acid metabolites in human nasal polyps. Acta Otolaryngol (Stockh) 1993; 501: 85-7.
12. Yamashita T, Tsuji H, Maeda N, Tomoda K, Kumazawa T. Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinol Suppl 1989; 8: 15-24.
13. Dahlén SE, Dahlén B, Kumlin M, Björck T, Ihre E, Zetterström O. Clinical and experimental studies of leukotriens as mediators of airway obstruction in humans. Adv Prostaglandin Thromboxane Leukot Res 1994; 22: 155-66.
14. Björck T, Harada Y, Dahlén B, et al. Further evidence that leukotrienes are the major mediators of allergic constriction in human bronchi. Adv Prostaglandin Thromboxane Leukot Res 1990; 21: 429-33.
15. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447-51.
16. Kumlin M, Dahlèn B, Björck T, Zetterström O, Granström E, Dahlèn SE. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis 1992; 146: 96-103.
17. Sladek K, Dworski R, Soja J, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Resp Crit Care Med 1994; 149: 940-6.
18. Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Arachidonic acid metabolism in monocytes of aspirin-sensitive asthmatis patients before and after oral aspirin challenge. J Allergy Clin Immunol 1992; 90: 636-45.
19. Szczeklik A. Prostaglandin E2 and aspirin-induced asthma. Lancet 1995; 345: 1056.
20. Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin induced asthma. Am J Resp Crit Care Med 1996; 153: 567-71.
21. Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J 1995; 8: 1203-13.
22. Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin induced asthma. Thorax 1994; 49: 749-56.
23. Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Resp Crit Care Med 1996; 153: 572-5.
24. Schäfer D, Lindenthal U, Wagner M, Bölcskei P, Baenkler HW. PGE2 inhibits pLT and TXB-release of human lung biopsy specimens. Allergy 1995; 50 (Suppl 26): 268.
25. Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 1995; 96: 148-56.